Biotechnology

BeOne Medicines

Today’s Key News Recap

03692

09618

89618

02423

BEKE

06160

688235

HJDD

01810

81810

HXXD

XIACY

HERO

01519

09896

MNSO

01024

81024

HKUD

0526 | Dolphin Research Focus: 🐬 Macro/Industry. 1) The US and Iran reached a framework for an MoU; Iran would reopen the Strait of Hormuz within 30 days of signing, the US would unfreeze $12bn of Iranian assets, and both sides would implement a ceasefire.This would significantly ease near-term Middle East tensions and stabilize the global energy supply chain (about 30% of crude flows through the strait). It supports a pullback in oil and a rebound in energy stocks.However, the arrangement is temporary and does not address core issues such as Iran's nuclear program. Longer-term execution remains uncertain.2) Hang Seng Indexes Company announced the results of its regular quarterly index rebalancing. ...

HANSOH PHARMA

JD-SW

JD.com

JD-SWR

BEKE-W

Beigene

BEONE MEDICINES

JD HK SDR 10to1

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

Global X Video Games & Esports ETF

J&T EXPRESS-W

Miniso

KUAISHOU-W

KUAISHOU-WR

Kuaishou HK SDR 5to1

Hang Seng Index

BEKE rolls out HK buyback shield; Xiaomi faces earnings test tonight | Daily News Recap

BeiGene and Amgen's Bispecific Antibody Aytept Approved by NMPA for SCLC Treatment

Shanghai Pharma Holdings and BeiGene Hold Strategic Cooperation Signing Ceremony

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

BeiGene's Brukinsa Approved by FDA

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BeOne Medicines released FY2026 Q1 earnings on May 6 Pre-Market (BJT), actual revenue CNY 10.46 B (forecast CNY 9.93 B), actual EPS CNY 1.0368

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

BeOne Medicines to Release FY2026 Q1 Earnings on May 6 Pre-Market (BJT), Forecast Revenue CNY 9.835 B

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

BeiGene's Wholly-Owned Subsidiary Signs Exclusive Option, License and Collaboration Agreement with Huahui Anjian

BGT Biotechnology Reports First Yearly Profit, Innovation Pharmaceuticals Reach Critical Milestone

BGNE

BeOne Medicines Ltd (HK:6160) filed a Form S-8 with the U.S. SEC to register shares under its equity incentive plans, enhancing global compensation capabilities. The company is a Swiss-incorporated biopharmaceutical firm listed in Hong Kong. Analysts maintain a 'Buy' rating with a HK$243.80 price target, while technical signals indicate a 'Sell'.

Tip Ranks

BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans

BeOne Medicines Ltd (HK:6160) announced its board structure and committee allocations to strengthen corporate governance. Chairman and CEO John V. Oyler leads the executive team, supported by independent directors chairing key committees for audit, compensation, nominations, and scientific advisory. This framework aims to balance management oversight with independent guidance on strategy and compliance. The company operates in the biopharmaceutical sector with a market cap of HK$242.5B.

BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance

01801

03690

YINN

YANG

159191

As of June 2nd, 14:33, the Hong Kong Stock Connect Technology ETF E Fund (159191) rose by 3.68%, with the latest price reported at 0.99 yuan. Its top ten weighted stocks showed mixed performance, with Tencent Holdings up 9.77%, MEITUAN-W up 8.56%, and Alibaba-W up 5.7%; BeOne Medicines and INNOVENT BIO saw slight declines. The fund ranks 6th among its peers, with a trading volume of 18.8008 million yuan and a turnover rate of 23.47%

- As of June 2, 14:33, the Hong Kong Stock Connect Technology ETF (159191) rose 3.68% to ¥0.99.  
- Among its top ten weighted stocks, Alibaba increased by 5.7%, Tencent by 9.77%, and Meituan by 8.56%.  
- The fund's latest scale ranks sixth among ETFs tracking the same index, with a trading amount of ¥18.80 million and a turnover rate of 23.47%.

同壁财经

INNOVENT BIO

MEITUAN

Direxion FTSE China Bull 3X

Direxion FTSE China Bear 3X

E Fund CNI HK Connect Technology ETF

BABA-W

Alibaba

TENCENT

BYD COMPANY

SMIC

WUXI BIO

BABA-WR

Alibaba HK SDR 5to1

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

MEITUAN-WR

Meituan

Meituan HK SDR 5to1

BYD HK SDR 10to1

BYD Company

BYD Company Limited

BYD COMPANY-R

SMIC HK SDR 5to1

WuXi Biologics

E Fund CNI HK Connect Technology ETF (159191) rose 3.68%

09926

159992

512010

Akeso announced that ivonescimab plus chemotherapy significantly improved overall survival (HR=0.66) versus tislelizumab plus chemotherapy in first-line sq-NSCLC, per the Phase III HARMONi-6 study. These landmark results will be presented at ASCO 2026 and published in The Lancet, marking the first China-originated oncology drug selected for an ASCO Plenary Session.

prnewswire

AKESO

Tianhong CNI BIOMEDICINE ETF

Direxion S&P Biotech Bull 3X

Huaan Hang Seng Biotech ETF

E Fund CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

ChinaAMC CSI Biotechnology Theme ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bear 3X

E Fund Hang Seng SCHK Innovative Drug ETF

Invesco Nasdaq Biotechnology ETF

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Ark Genomic Revolution ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

iShares Global Healthcare

China Universal 800 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

VG Health

ChinaAMC SSE STAR Biology and Medicine ETF

VanEck Biotech ETF

Guotai SSE STAR Brand Name Drug ETF

ALPS Medical Breakthrough

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

China Southern Hang Seng Biotech ETF(QDII)

09:00 ETHARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

SMMT

Akeso's HARMONi-6 study in China shows Ivonescimab combined with chemotherapy achieved a statistically significant overall survival benefit compared to Tislelizumab plus chemotherapy for first-line treatment of squamous non-small cell lung cancer (NSCLC).

StockTitan

Summit Therapeutics

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China | SMMT Stock News

688271

United Imaging Healthcare showcased its full-process ecological closed-loop output at the Global Radiation Oncology Conference, with its core product uRT-linac 506c receiving CE MDR certification, marking the ecological output of high-end medical equipment in China. BeOne Medicines' Class 1 new drug BG-75202 has obtained clinical trial approval, targeting tumor resistance mechanisms and is at the forefront of the industry. These innovations reflect the technological breakthroughs and global market growth potential of Chinese medical enterprises

United Imaging Healthcare

STAR Biology and Medicine

The leading innovative drug company frequently reports good news, with solid innovation reinforcing long-term value

BeOne Medicines' BCL-2 inhibitor Sotorasib has received accelerated approval from the FDA, becoming the first new BCL-2 targeted drug approved in the United States in the past decade, suitable for relapsed/refractory mantle cell lymphoma. The company expects net profit in the first quarter to exceed 1.6 billion yuan, with revenue expectations raised to between 43.6 billion and 45.2 billion yuan, maintaining a gross margin of 80%. This move is expected to break the reliance on a single product and enhance medication adherence among patients and doctors

BambooWorks

Amgen

BeOne Medicines is expected to break the "single product dependence" with a net profit exceeding 1.6 billion yuan in the first quarter

BeOne Medicines(688235.SH)